US Patent

US10959991 — Amlodipine formulations

Method of Use · Assigned to Silvergate Pharmaceuticals Inc · Expires 2037-10-06 · 11y remaining

Vulnerability score 62/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects stable amlodipine oral liquid formulations and methods of using them to treat hypertension and Coronary Artery Disease.

USPTO Abstract

Provided herein are stable amlodipine oral liquid formulations. Also provided herein are methods of using amlodipine oral liquid formulations for the treatment of certain diseases including hypertension and Coronary Artery Disease (CAD).

Drugs covered by this patent

amlodipine-benzoate (AMLODIPINE BENZOATE)

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-39`	—	amlodipine-benzoate

Patent Metadata

Patent number: US10959991
Jurisdiction: US
Classification: Method of Use
Expires: 2037-10-06
Drug substance claim: No
Drug product claim: No
Assignee: Silvergate Pharmaceuticals Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.